Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders.
- Published in:
- CNS Drugs, 2023, v. 37, n. 5, p. 399, doi. 10.1007/s40263-023-01007-6
- By:
- Publication type:
- Article
Works matching IS 11727047 AND DT 2023 AND VI 37 AND IP 5
Results: 7
1
2
Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis.
- Published in:
- CNS Drugs, 2023, v. 37, n. 5, p. 381, doi. 10.1007/s40263-023-01005-8
- By:
- Publication type:
- Article
3
New Pharmacological Approaches to the Management of Premenstrual Dysphoric Disorder.
- Published in:
- CNS Drugs, 2023, v. 37, n. 5, p. 371, doi. 10.1007/s40263-023-01004-9
- By:
- Publication type:
- Article
4
Correction to: Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use.
- Published in:
- CNS Drugs, 2023, v. 37, n. 5, p. 475, doi. 10.1007/s40263-023-01003-w
- By:
- Publication type:
- Article
5
Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis.
- Published in:
- CNS Drugs, 2023, v. 37, n. 5, p. 441, doi. 10.1007/s40263-023-01002-x
- By:
- Publication type:
- Article
6
A Retrospective Real-Life Multicenter Study on Concurrent Oral Preventive Treatments in Patients with Chronic Migraine Treated with OnabotulinumtoxinA.
- Published in:
- CNS Drugs, 2023, v. 37, n. 5, p. 453, doi. 10.1007/s40263-023-01001-y
- By:
- Publication type:
- Article
7
Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use.
- Published in:
- CNS Drugs, 2023, v. 37, n. 5, p. 467, doi. 10.1007/s40263-023-01000-z
- By:
- Publication type:
- Article